7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-09-30 2019-06-30 2019-03-31 2018-09-30 2018-06-30 2018-03-31 2017-09-30 2017-06-30 2017-03-31 2016-09-30 2016-06-30 2016-03-31 2015-09-30 2015-06-30 2015-03-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 
      
    		                                                    
      cash flows from operating activities:
    		                                                    
      net income
    		21,631,000 -148,441,000 -67,613,000 24,890,000 -10,305,000 -81,836,000 -66,483,000 -84,473,000 -19,640,000 -18,267,000 -85,231,000 -86,091,000 -101,650,000 -55,433,000 -73,774,000 28,739,000 -16,186,000 31,078,000 32,298,000 23,717,000 33,703,000 -59,132,000 -62,007,000 -59,806,000 -80,762,000 -27,654,000 -6,201,000 -43,114,000 -46,442,000 -17,528,000 -30,995,000 -14,977,000 15,532,000 -11,978,000 128,247,000 -43,241,000 -118,037,000 -50,013,000 -26,072,000 -45,091,000 -17,430,000 -60,801,000 -4,353,000 -34,762,000 -1,040,000 -9,646,000 -10,243,000 -8,611,000   -5,746,000 -5,704,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                                                    
      depreciation and amortization
    		22,740,000 23,027,000 23,487,000 24,163,000 24,154,000 25,820,000 25,982,000 26,322,000 26,547,000 26,446,000 26,460,000 26,386,000 27,995,000 27,814,000 19,191,000 18,964,000 20,572,000 19,989,000 20,067,000 20,977,000 22,266,000 22,052,000 23,804,000 23,661,000 23,816,000 23,922,000 24,761,000 24,757,000 25,396,000 25,551,000 25,730,000 25,832,000 24,581,000 22,199,000 12,388,000 4,160,000 3,525,000 3,678,000 4,027,000 3,564,000 4,568,000 3,768,000 3,451,000 3,429,000 2,713,000 2,665,000 2,454,000 2,328,000 972,000 776,000 1,085,000 997,000 
      non-cash interest
    		2,309,000 56,908,000 4,649,000 4,615,000 4,295,000 3,843,000 693,000 693,000 686,000 678,000 693,000 693,000 686,000 678,000 2,225,000 2,183,000 2,396,000 2,585,000 2,355,000 2,617,000 2,539,000 2,483,000 1,690,000 -142,000 3,010,000 1,361,000 1,355,000 843,000 650,000 654,000 640,000 655,000 659,000 749,000                   
      amortization of deferred financing costs
    		138,000 4,529,000 430,000 382,000 427,000 519,000 314,000 310,000 302,000 296,000 298,000 294,000 288,000 281,000 182,000 179,000 202,000 222,000 221,000 215,000 208,000 203,000 198,000 -97,000 405,000 56,000 56,000 43,000 56,000 56,000 56,000 101,000 37,000 37,000 280,000 144,000 751,000 100,000 1,630,000 177,000 177,000 650,000 198,000 145,000         
      losses from investments in investees
    		3,000 0 9,000 4,000 0 3,000 8,000 20,000 42,000 37,000 24,000 43,000 267,000 49,000 466,000 53,000 67,000 43,000 47,000 110,000 189,000 134,000 294,000 271,000 1,854,000 1,873,000 7,213,000 2,456,000 4,013,000 5,627,000 2,131,000 814,000 1,988,000 2,345,000 3,502,000 804,000 1,761,000 60,000 370,000 2,056,000 3,595,000 1,600,000 2,371,000 3,890,000         
      equity-based compensation – employees and non-employees
    		2,969,000 2,212,000 2,616,000 2,784,000 2,609,000 2,590,000 2,667,000 3,219,000 2,810,000 2,717,000 3,194,000 3,390,000 4,308,000 7,617,000 3,703,000 3,822,000 3,460,000 2,647,000 2,170,000 2,740,000 1,586,000 2,451,000 3,428,000 3,122,000 4,457,000 5,077,000 5,578,000 5,936,000 6,448,000 6,151,000 9,693,000 8,834,000 8,798,000 17,307,000 3,675,000 6,708,000 7,382,000 3,095,000 3,414,000 3,579,000 3,572,000 408,000 1,798,000 5,205,000    1,180,000     
      impairment of intangible assets
    		                                                    
      realized gain on disposal of fixed assets and sales of equity securities
    		12,000 -72,000 -3,786,000 -9,420,000 -22,000 -47,000     359,000 -337,000 -538,000 61,000 1,562,000 -32,338,000 -107,000 -3,039,000                                   
      change in fair value of equity securities and derivative instruments
    		-287,000 -646,000 2,380,000 -35,378,000 -60,499,000 1,251,000 3,241,000 8,260,000 13,276,000 -7,130,000 49,709,000 30,402,000 72,425,000 1,299,000 2,048,000 1,046,000 1,152,000 -279,000  7,768,000 -15,774,000 9,259,000 11,747,000 7,256,000 -1,825,000 473,000 -11,718,000 -3,101,000                         
      inducement expense and loss on debt conversion
    		0                                                    
      deferred income tax benefit
    		18,287,000 -15,713,000 -7,424,000 12,172,000 -1,797,000 -2,680,000  5,554,000 1,651,000 102,000  -39,941,000 13,414,000 -22,356,000        613,000 1,897,000 520,000 -352,000 -12,515,000 683,000 -2,709,000 -23,327,000 -13,803,000 -9,236,000 -21,983,000 13,245,000 -22,244,000        405,000 -700,000 98,000         
      gain on sale of assets
    		                                                    
      changes in assets and liabilities:
    		                                                    
      accounts receivable
    		4,389,000 -3,815,000 22,930,000 327,000 5,835,000 9,518,000 -5,330,000 90,563,000 -89,186,000 7,364,000 -1,450,000 34,188,000 51,443,000 44,421,000 -22,702,000 7,582,000 55,590,000 -35,238,000 -43,182,000 -25,716,000 -80,776,000 -763,000 7,655,000 -3,959,000 -439,000 -4,739,000 5,683,000 6,757,000 17,271,000 -13,094,000 -17,771,000 -10,586,000 -8,464,000 -9,924,000 -9,200,000 -4,709,000 -103,000 181,000 -3,764,000 -557,000 1,478,000 928,000 -1,094,000 -558,000 947,000 2,497,000 10,000 -2,691,000 804,000 -449,000 -1,476,000 -598,000 
      inventory
    		624,000 -478,000 -5,437,000 4,720,000 -542,000 2,274,000 11,115,000 1,333,000 1,443,000 1,306,000 2,348,000 8,450,000 12,327,000 -9,463,000 16,430,000 18,071,000 24,095,000 -27,912,000 -17,077,000 -38,660,000 -13,074,000 -8,831,000 -3,318,000 -3,750,000 -2,475,000 3,163,000 690,000 204,000 2,172,000 -393,000 -50,000 -963,000 -1,611,000 -152,000 -3,150,000 -647,000 -2,610,000 314,000 263,000 -1,676,000 940,000 -261,000 2,652,000 -1,439,000 -1,364,000 -1,122,000 1,112,000 -4,433,000 -1,910,000 863,000 1,826,000 1,391,000 
      other current assets and prepaid expenses
    		1,035,000 -5,053,000 2,735,000 -578,000 -7,265,000 -552,000 -3,056,000 8,941,000 60,181,000 -58,902,000 561,000 2,525,000 -9,114,000 2,612,000 15,216,000 166,000 -15,319,000 1,415,000 7,393,000 15,730,000 -1,890,000 -729,000 -5,032,000 2,522,000 -46,000 -574,000 -9,175,000 5,445,000 -6,549,000 -1,000,000 4,692,000 -10,001,000                     
      other assets
    		412,000 457,000 -967,000 680,000 -123,000 7,000 2,378,000 -751,000 -2,687,000 772,000 1,724,000 471,000 -771,000 511,000 -755,000 -373,000 133,000 1,255,000 -177,000 -209,000 -121,000 60,000 104,000 379,000 -243,000 -4,487,000 -15,000 -131,000 -195,000 -19,000 -235,000 -1,134,000 -715,000 1,447,000 1,774,000 -3,000 -509,000 554,000 2,482,000 1,429,000 -1,069,000 428,000 26,000 71,000 -438,000 66,000 4,000 7,000 -37,000 35,000 -62,000 80,000 
      accounts payable
    		-5,244,000 -3,388,000 11,475,000 -20,215,000 10,899,000 2,789,000 2,637,000 -20,019,000 7,451,000 12,759,000 15,612,000 -5,492,000 -35,651,000 16,143,000 -6,101,000 6,905,000 -73,882,000 62,231,000 33,898,000 20,014,000 -11,888,000 -4,865,000 17,710,000 9,174,000 3,713,000 -1,237,000 2,114,000 -10,206,000 2,574,000 -10,100,000 19,539,000 -2,936,000 -12,856,000 -349,000 -42,605,000 4,994,000 2,107,000 -542,000 -4,787,000 1,479,000 -474,000 1,970,000 436,000 -103,000 1,578,000 465,000 -525,000 -271,000 1,868,000 596,000 -1,761,000 -2,487,000 
      foreign currency measurement
    		-2,676,000 -1,348,000 -641,000 -6,213,000 1,413,000 1,225,000 -1,060,000 1,342,000 1,037,000 -2,355,000 -8,172,000 6,246,000 2,098,000 2,197,000 -37,000 4,914,000 -3,478,000 946,000 -2,403,000 1,295,000 -2,133,000 56,000 16,000 154,000 -23,000 134,000 -66,000 -11,000 378,000 299,000 -69,000 -28,000 -152,000 -253,000 476,000 -173,000 473,000 1,832,000 152,000 -976,000 -977,000 -1,859,000 790,000 -340,000 290,000 -95,000 349,000 -458,000     
      accrued expenses and other liabilities
    		-420,000 -24,246,000 -19,397,000 41,513,000 4,486,000 -1,047,000 -3,974,000 -6,445,000 -4,474,000 9,547,000 -8,150,000 -12,653,000 -33,801,000 -36,177,000 31,964,000 -16,527,000 -22,034,000 -27,126,000 -7,160,000 41,403,000 43,737,000 3,848,000 -2,333,000 -10,155,000 12,250,000 11,261,000 -6,991,000 -8,829,000 -8,055,000 12,187,000 -16,024,000 2,563,000 20,326,000 13,126,000 34,047,000 -1,672,000 4,413,000                
      net cash from operating activities
    		-34,647,000 -83,420,000 -34,554,000 -77,079,000 -26,435,000 -35,566,000 -38,294,000 33,109,000 -365,000 -22,647,000 -31,620,000 -32,236,000 -11,477,000 -19,856,000 -5,643,000 33,396,000 -15,453,000 26,037,000 34,258,000 63,011,000 -14,423,000 -43,370,000 -23,866,000 -53,631,000 -48,988,000 -21,883,000 -17,079,000 -35,520,000 -37,607,000 -22,664,000 -33,919,000 -31,896,000 42,842,000 -9,206,000 -31,363,000 -34,055,000 238,793,000 -21,077,000 -15,495,000 -29,046,000 -26,050,000 -11,472,000 -5,925,000 -14,745,000 -5,728,000 -1,927,000 -6,261,000 -11,499,000 -6,588,000 -3,346,000 -3,881,000 -4,685,000 
      cash flows from investing activities:
    		                                                    
      investments in investees
    		0 335,000 -8,000,000    0 0 0 -5,000,000             0 0 -1,200,000 0 0 -1,000,000 -1,625,000   -3,250,000 -5,671,000 -250,000 -655,000   -89,000 0 -500,000 -4,100,000 0 -10,841,000 -2,500,000 -696,000 0 0 -2,700,000     
      proceeds from sale of equity securities
    		0 0 51,655,000                       230,000 0 1,286,000          0 34,000 1,297,000 18,928,000            
      purchase of marketable securities
    		                            -1,000   -1,000         0 0   3,117,000 -11,806,000 -2,120,000 -14,997,000 0 -30,180,000 -9,998,000 -59,983,000 
      proceeds from the sale of property, plant and equipment
    		13,000 114,000 67,000 66,000 55,000 48,000 1,604,000 267,000 522,000 320,000 450,000 631,000 522,000 348,000 51,000 65,810,000 105,000 60,000 53,000 127,000 58,000 7,000 243,000   230,000 299,000 541,000 581,000 303,000 3,095,000 374,000         5,000            
      capital expenditures
    		-3,135,000 -3,283,000 -3,194,000 -7,937,000 -7,217,000 -4,443,000 -3,022,000 -4,203,000 -6,013,000 -3,037,000 -6,336,000 -7,612,000 -5,379,000 -5,251,000 -6,730,000 -7,234,000 -8,947,000 -9,245,000 -6,797,000 -9,736,000 -11,523,000 -5,626,000 -2,434,000 -3,500,000 -2,932,000 -12,031,000 -6,819,000 -5,973,000 -15,256,000 -7,268,000 -9,537,000 -4,149,000 -3,054,000 -9,812,000 -2,983,000 -1,076,000 -363,000 -1,468,000 -1,606,000 -861,000 -971,000 -937,000 -1,299,000 -755,000 -408,000 -656,000 -233,000 -175,000 -704,000 -707,000 -434,000 -108,000 
      free cash flows
    		-37,782,000 -86,703,000 -37,748,000 -85,016,000 -33,652,000 -40,009,000 -41,316,000 28,906,000 -6,378,000 -25,684,000 -37,956,000 -39,848,000 -16,856,000 -25,107,000 -12,373,000 26,162,000 -24,400,000 16,792,000 27,461,000 53,275,000 -25,946,000 -48,996,000 -26,300,000 -57,131,000 -51,920,000 -33,914,000 -23,898,000 -41,493,000 -52,863,000 -29,932,000 -43,456,000 -36,045,000 39,788,000 -19,018,000 -34,346,000 -35,131,000 238,430,000 -22,545,000 -17,101,000 -29,907,000 -27,021,000 -12,409,000 -7,224,000 -15,500,000 -6,136,000 -2,583,000 -6,494,000 -11,674,000 -7,292,000 -4,053,000 -4,315,000 -4,793,000 
      proceeds from labcorp sales including escrow released
    		                                                    
      net cash from investing activities
    		194,648,000 -2,834,000 40,528,000 247,784,000 -7,162,000 -4,395,000 -1,418,000 -3,572,000 -5,491,000 -7,717,000 -7,872,000 -4,682,000   -8,679,000 54,576,000 -8,842,000 -1,106,000 -6,744,000 5,501,000 -11,465,000 -5,619,000 -2,191,000 -3,191,000 -4,132,000 -11,571,000 -6,520,000 -5,146,000 -16,301,000 -9,970,000 -6,442,000 19,486,000 -23,647,000 -10,062,000 7,174,000 -98,095,000 -363,000 -1,545,000 -3,067,000 -264,000  45,292,000 -53,199,000 -649,000 8,430,000 -10,801,000 -4,526,000 -17,872,000 39,143,000 12,100,000   
      cash flows from financing activities:
    		                                                    
      issuance of 3.00% convertible senior notes
    		   0 0 230,000,000                                      170,184,000         
      issuance of 2044 notes
    		                                                    
      debt issuance costs
    		   -4,823,000 0 -8,562,000         0        0 0 -7,762,000                            
      share repurchase
    		-15,278,000   -23,759,000 0 -50,000,000                                               
      proceeds from the exercise of common stock options
    		0 -211,000 88,000 0    28,000    -463,000                                         
      repurchase of 2029 convertible notes
    		                                                    
      borrowings on lines of credit
    		7,869,000 11,026,000 5,610,000 130,648,000 154,108,000 163,703,000 156,360,000 173,468,000 176,562,000 165,288,000 165,971,000 209,081,000 -964,699,000 1,649,166,000 358,072,000 343,844,000 510,584,000 472,213,000 408,787,000 305,428,000 207,253,000 186,398,000 59,658,000 4,235,000 35,460,000 3,651,000 12,206,000 6,611,000 30,020,000 37,699,000 7,825,000 6,320,000 4,248,000 5,248,000 100,321,000 5,880,000 5,158,000 5,068,000 10,008,000 4,250,000 9,964,000 9,259,000 6,926,000 8,428,000         
      repayments of lines of credit
    		-8,797,000 -9,841,000 -9,546,000 -141,045,000 -156,015,000 -168,241,000 -160,112,000 -171,391,000 -172,799,000 -175,407,000 -155,741,000 -200,173,000 977,333,000 -1,657,193,000 -357,441,000 -348,325,000 -510,477,000 -479,713,000 -400,766,000 -360,558,000 -194,365,000 -188,009,000 -79,653,000 -43,511,000 -35,313,000 -7,511,000 -8,504,000 -12,420,000 -7,118,000 -6,008,000 -7,517,000 -9,560,000 -41,992,000 -7,349,000 -93,522,000 -5,173,000 -4,849,000 -7,252,000 -8,586,000 -5,985,000 -11,291,000            
      settlement of convertible notes
    		62,208,000                                                    
      net cash (provided by) used in financing activities
    		                                                    
      effect of exchange rate changes on cash, cash equivalents and restricted cash
    		-316,000 1,461,000 2,110,000                                                  
      net decrease (increase) in cash, cash equivalents and restricted cash
    		                                                    
      cash, cash equivalents and restricted cash at beginning of period
    		0 0 445,615,000                                                  
      cash, cash equivalents and restricted cash at end of period
    		143,479,000 -164,282,000 449,677,000                                                  
      supplemental information:
    		                                                    
      interest paid
    		10,139,000 6,305,000 13,762,000 9,465,000 392,000 3,125,000 -2,613,000 6,544,000 374,000 3,830,000 401,000 3,465,000 134,000 3,420,000 129,000 3,503,000 194,000 4,689,000 251,000 5,079,000 566,000 5,012,000 5,673,000 4,900,000 511,000 846,000 144,000 641,000 661,000 198,000 550,000 1,619,000 277,000 623,000 1,193,000 156,000 1,568,000 2,451,000 351,000 2,420,000  2,808,000 76,000 242,000  272,000 164,000 177,000  289,000 254,000 65,000 
      income taxes paid, net of refunds
    		763,000 17,802,000 2,059,000 2,225,000 513,000 1,063,000 4,535,000 -1,508,000 208,000 477,000 3,566,000 -176,000 3,584,000 1,063,000 460,000 1,819,000 2,220,000 1,470,000 -1,051,000   799,000 971,000 1,110,000 1,022,000 -1,368,000 2,959,000 2,292,000                         
      non-cash financing:
    		                                                    
      shares issued upon the conversion of:
    		                                                    
      common stock options, warrants, and restricted stock units surrendered in net exercise
    		0   0                                                 
      net cash from financing activities
    		 -79,489,000 -4,022,000 206,140,000 -2,115,000 20,613,000 -3,751,000 2,105,000 3,462,000 -13,119,000 10,144,000 8,444,000 12,274,000 -7,891,000 832,000 -4,256,000 265,000 -7,192,000 8,108,000 -54,461,000 12,888,000 -1,611,000 -19,995,000 -39,276,000 163,875,000 -3,005,000 4,020,000 49,191,000 22,902,000 31,741,000 2,174,000 960,000 -37,986,000 53,000 14,694,000 4,670,000 13,812,000 7,135,000 -3,905,000 -96,000 17,037,000 2,813,000 -3,317,000 169,641,000 1,048,000 -1,774,000 1,879,000 4,878,000 -8,356,000 -146,000 -9,744,000 105,163,000 
      net decrease in cash, cash equivalents and restricted cash
    		                                                    
      loss on conversion convertible senior notes
    		   -32,000 0 757,000                                               
      redemption of 2025 notes and 2033 senior notes
    		  -174,000 0 0 -146,287,000                                               
      net increase in cash, cash equivalents and restricted cash
    		  4,062,000                                                  
      change in fair value of contingent consideration
    		      -13,000 -1,125,000 -34,000 136,000 -627,000 -754,000 175,000 -106,000 -147,000 -497,000 -102,000 -957,000 -5,323,000 1,083,000 1,111,000 -860,000 -1,109,000 -3,775,000 4,806,000 1,193,000 -15,358,000 1,759,000 -11,213,000 4,367,000 2,371,000 3,093,000 10,758,000 1,753,000 1,635,000 -339,000 5,175,000 19,592,000 1,876,000 2,610,000 2,774,000 252,000 2,577,000 1,344,000 -2,339,000        
      proceeds from labcorp sale
    		                                                    
      assets acquired by finance leases
    		      -510,000 532,000 -779,000 960,000                                           
      operating lease right-of-use assets in exchange for lease obligations
    		                                                    
      fair value of shares received related to milestone achieved from genedx holdings
    		                                                    
      contract liabilities
    		      -129,000 -4,000 0 2,000 -256,000 -56,000 -13,000 -4,000 -2,895,000 -5,591,000 -6,635,000 -790,000 -672,000 -691,000 5,425,000 -9,451,000 -19,845,000 -18,942,000 -18,073,000 -19,719,000 -15,454,000 -15,358,000                         
      effect of exchange rate changes on cash and cash equivalents
    		    649,000 -894,000 723,000 -1,129,000 -328,000 1,122,000 1,701,000 -1,146,000 -1,115,000 221,000 -399,000 -874,000 284,000 -447,000 295,000 631,000 82,000 -322,000 -396,000 -37,000 22,000 -204,000 17,000 -81,000 838,000 371,000 506,000 81,000              -241,000 -39,000 95,000  -222,000 45,000 14,000 
      net decrease in cash and cash equivalents
    		    -35,063,000 -20,242,000    -42,361,000               110,777,000 -36,663,000   -30,168,000 -522,000 -37,681,000                      
      cash and cash equivalents at beginning of period
    		    0 95,881,000 0 0 0 153,191,000 0 0 0 134,710,000 0 0 0 72,211,000 0 0 0 85,452,000 0 0 96,473,000 0 0 91,499,000 0 0 168,733,000 0 0 193,598,000 0 0 96,907,000 0 0 185,798,000 0 0 0 27,361,000   0 71,516,000  0 0 18,016,000 
      cash and cash equivalents at end of period
    		    -35,063,000 75,639,000 -42,740,000 30,513,000 -2,722,000 110,830,000 -27,647,000 -29,620,000 108,177,000 102,281,000 -13,889,000 82,842,000 -23,746,000 89,503,000 35,917,000 14,682,000 -12,918,000 34,530,000 -46,448,000 -96,135,000 207,250,000 -36,663,000 -19,562,000 99,943,000 -30,168,000 -522,000 131,052,000 -11,369,000 -18,958,000 174,973,000 -9,073,000 -126,975,000 348,192,000 -15,752,000 -22,386,000 156,396,000 29,964,000 36,773,000 -62,535,000 181,596,000  -14,743,000 -8,947,000 47,118,000  8,386,000 -9,030,000 47,879,000 
      non-cash revenue from the transfer of intellectual property
    		              0                                      
      loss on conversion of the 2025 notes
    		              0 0                                     
      gain on sale of genedx
    		          -3,194,000 0                                         
      deferred income tax provision
    		              7,781,000 -101,000 3,512,000 -1,033,000 13,666,000 946,000                                 
      changes in assets and liabilities, net of the effects of acquisitions:
    		                                                    
      proceeds from sale of investments
    		              0 0 0 8,079,000 0                                  
      acquisition of businesses, net of cash acquired
    		                                                    
      net activity from the exercise of common stock options and warrants
    		                                                    
      redemption of 2033 senior notes
    		      0 0 0 -3,000,000             0 0 -28,800,000                            
      net increase in cash and cash equivalents
    		      -42,740,000 30,513,000   -27,647,000 -29,620,000 108,177,000 -32,429,000 -13,889,000   17,292,000   -12,918,000 -50,922,000 -46,448,000     8,444,000    -11,369,000 -18,958,000 -18,625,000 -9,073,000 -126,975,000 251,285,000 -15,752,000 -22,386,000 -29,402,000 29,964,000 36,773,000 -62,535,000 154,235,000 3,933,000 -14,743,000 -8,947,000 -24,398,000  8,386,000 -9,030,000 29,863,000 
      operating lease right-of-use assets obtained in exchange for lease obligations
    		      23,397,000                                              
      2025 convertible notes
    		               0                                     
      common stock options and warrants, surrendered in net exercise
    		          86,000 527,000           0 0 20,000 0   0 850,000 696,000 25,000 290,000 35,000 2,000 1,000 14,238,000                
      issuance of common stock for acquisition of modex
    		          0 2,288,000                                         
      fair value of shares included in consideration from genedx holdings
    		                                                    
      realized loss on disposal of fixed assets and sales of equity securities
    		       -631,000 230,000 1,845,000           54,000 102,000                               
      proceeds from sale of genedx
    		           0                                         
      acquisition of businesses, net of cash
    		           2,299,000                       15,812,000   12,000 -1,495,000 -200,000  20,450,000 0 78,000 -8,580,000 -8,339,000   -17,648,000 0 0 -10,538,000 
      fair value of shares received included in consideration from genedx holdings
    		                                                    
      issuance of common stock
    		                                                    
      fair value of shares included in consideration from sema4
    		           0                                         
      net cash from used in investing activities
    		             -4,903,000                                       
      proceeds from the exercise of common stock options and warrants
    		             136,000 201,000 413,000 158,000 308,000 87,000    0 0 -3,000 855,000   0 50,000 1,866,000 4,200,000 -242,000 2,154,000 7,814,000 4,654,000 12,712,000 9,319,000 1,108,000 1,639,000 18,364,000 3,542,000 524,000 995,000 577,000        
      asset impairment charges
    		                                                    
      issuance of 2023 convertible notes, including to related parties
    		                                                    
      operating lease right-of-use assets due to adoption of asu no. 2016-02
    		                      6,186,000 -3,637,000 33,277,000                            
      operating lease liabilities due to adoption of asu no. 2016-02
    		                      6,190,000 -3,695,000 33,744,000                            
      realized gain on disposal of fixed assets and sales of equity securities and other
    		                                                    
      change in fair value of equity securities and derivative instruments and other
    		                                                    
      impairment of assets
    		                      0 0 655,000                            
      issuance of convertible notes, including to related parties
    		                      0 0 200,293,000                            
      income taxes paid (received), net of refunds
    		                                                    
      gain on disposal of fixed assets
    		                       -64,000 284,000 529,000 -234,000 -261,000                         
      issuance of 2033 senior notes, including to related parties
    		                         0                           
      issuance of capital stock for contingent consideration settlement:
    		                                                    
      opko health europe
    		                            0   0 0 313,000 0                  
      issuance of 2033 senior notes, net, including related parties
    		                           55,000,000                         
      realized gain on equity securities and disposal of fixed assets
    		                            -210,000 524,000 -2,997,000                      
      change in fair value of derivative instruments
    		                            7,550,000 -5,482,000 -4,037,000 5,701,000 -1,235,000 1,423,000 -32,244,000 16,556,000 49,788,000                
      deferred revenue
    		                            -8,124,000 -16,661,000 -17,357,000 -20,318,000 -18,129,000 -17,809,000 -17,664,000 -18,312,000 282,238,000                
      maturities of short-term marketable securities
    		                                        25,011,000    14,997,000     45,000,000   
      acquisition of intangible assets
    		                                                    
      income taxes paid
    		                            1,578,000 3,473,000 848,000 873,000 5,667,000 1,505,000 626,000 530,000 227,000 -230,000            8,000   
      transition therapeutics, inc.
    		                                                    
      opko renal
    		                                                    
      issuance of stock for investment in xenetic
    		                                                    
      issuance of capital stock to acquire or contingent consideration settlement:
    		                                                    
      revenue from receipt of equity
    		                                  -20,000 -60,000 -60,000 -60,000 -60,000 -60,000 -60,000 -60,000 -80,000 -12,540,000   -51,000 -51,000     
      loss on conversion of 3.00% convertible senior notes
    		                                    321,000    0            
      gain on deconsolidation of scivac
    		                                                    
      cash from non-controlling interest
    		                                  0 -691,000 791,000                
      2033 senior notes
    		                                  28,127,000 12,284,000 79,888,000 0               
      bio-reference laboratories, inc.
    		                                                    
      eirgen pharma limited
    		                                  0                  
      realized gain on equity securities
    		                                                    
      realized gain on sale of equity securities
    		                                  0 0 -216,000 1,000 -1,000 -1,273,000 -18,928,000            
      (gain) loss on conversion of 3.00% convertible senior notes
    		                                  -1,234,000                  
      prepaid expenses and other current assets
    		                                 -6,883,000 -5,367,000 198,000 944,000 163,000 2,179,000 1,145,000 950,000 491,000 -2,000 -2,570,000 -1,565,000 6,000 -837,000 -481,000 -167,000 317,000 286,000 -379,000 
      effect of exchange rate on cash and cash equivalents
    		                                 590,000 422,000 505,000 -957,000 -265,000 81,000 4,000 104,000 140,000 -94,000 -12,000         
      non-cash interest on 2033 senior notes
    		                                  495,000 625,000 1,056,000 1,039,000 1,780,000 1,777,000             
      (recovery of) benefit from bad debts
    		                                  7,682,000 452,000 174,000 48,000               
      benefit from inventory obsolescence
    		                                  -27,000 490,000 220,000 190,000 246,000 337,000 486,000 256,000 334,000 939,000         
      in-process research and development
    		                                     0               
      deferred income tax (benefit) expense
    		                                                    
      contingent consideration payments
    		                                     0               
      pharmsynthez common stock received
    		                                     0 0 6,264,000             
      issuance of capital stock to acquire:
    		                                                    
      inspiro
    		                                     0               
      opko uruguay ltda.
    		                                                    
      gain on conversion of 3.00% convertible senior notes
    		                                     0               
      loss on sale of property, plant and equipment
    		                                        4,000            
      accrued expenses
    		                                     1,997,000 4,344,000 -8,007,000 -6,149,000 2,337,000 5,031,000 -440,000 1,902,000 546,000 -1,340,000 1,253,000 -1,264,000 1,755,000 -649,000 -254,000 
      payment of series d dividends, including related parties
    		                                        0 0 0 -3,015,000         
      rxi common stock received
    		                                         0 0 12,500,000         
      series d preferred stock
    		                                         0 0 24,386,000         
      issuance of common stock to acquire:
    		                                                    
      opko biologics
    		                                                    
      opko brazil
    		                                         0           
      arama uruguay
    		                                     0 0 159,000             
      change in fair value of derivatives instruments
    		                                      -10,967,000 10,515,000 -2,202,000 27,793,000 -12,651,000 23,549,000         
      common stock options and warrants, net exercised
    		                                      2,836,000 657,000             
      benefit from (recovery of) bad debts
    		                                       -74,000   -52,000 381,000         
      income taxes paid (refunded)
    		                                       377,000             
      income from discontinued operations, net of tax
    		                                                    
      non-cash interest on convertible senior notes
    		                                        1,730,000 1,130,000 1,817,000 1,303,000         
      deferred income tax (benefit)/provision
    		                                                    
      changes in assets and liabilities of continuing operations, net of the effects of acquisitions:
    		                                                    
      cash from operating activities of continuing operations
    		                                        -26,050,000 -11,472,000 -5,925,000 -14,745,000  -2,023,000 -6,104,000 -11,574,000     
      cash from operating activities of discontinued operations
    		                                             96,000 -157,000 75,000     
      cash provided (or used) by investing activities from continuing operations
    		                                                    
      cash from investing activities from discontinued operations
    		                                                    
      net cash provided (or used) in investing activities
    		                                                    
      issuance of 3.00% convertible senior notes, net, including related parties
    		                                        0 0           
      issuance of common stock, net (including related parties) net
    		                                                    
      purchase of common stock held in treasury
    		                                                0 0   
      redemption of series a preferred stock (including related parties
    		                                                    
      benefit from bad debts
    		                                                    
      changes in assets and liabilities of continuing operations, net of theeffects of acquisitions:
    		                                                    
      3.00% convertible senior notes
    		                                                    
      common stock warrants, net exercised
    		                                         0 0 815,000         
      issuance of common stock, common stock options and warrants to acquire prolor
    		                                                    
      cytochroma
    		                                         0 0 146,902,000         
      farmadiet
    		                                                    
      realized gain on investments available for sale
    		                                          -8,474,000 -2,347,000         
      proceeds from sale of investments available for sale
    		                                          8,968,000 2,528,000         
      repayments of lines of credit and capital lease obligations
    		                                          -10,767,000 -6,951,000         
      supplemental information
    		                                                    
      cash flows from operating activities
    		                                                    
      cash provided in operating activities of discontinued operations
    		                                                    
      income taxes refunded
    		                                           -118,000   203,000 -6,000     
      silcon
    		                                           436,000         
      accretion of debt discount related to notes payable
    		                                                0 0 0 2,000 
      equity based compensation – employees and non-employees
    		                                                    
      benefit from (recovery of) inventory obsolescence
    		                                                    
      unrealized gains on derivative instruments
    		                                            -31,000        
      cash from operating activities from continuing operations
    		                                                -6,307,000    
      cash from operating activities from discontinued operations
    		                                                    
      cash from investing activities from continuing operations
    		                                                21,827,000    
      issuance of common stock, including related parties
    		                                                0 0 0 104,828,000 
      redemption of series a preferred stock including related parties
    		                                                    
      payment of series d dividends, including to related parties
    		                                                    
      repayments of line of credit with related party
    		                                                    
      cash and cash equivalents at beginning of year
    		                                                    
      cash and cash equivalents at end of year
    		                                                    
      (income) income from discontinued operations, net of tax
    		                                                    
      equity-based compensation - employees and non-employees
    		                                             1,112,000       
      income from investments in investees
    		                                             468,000 473,000 523,000  301,000 451,000 423,000 
      benefit from bad debt
    		                                                    
      revenue from receipt of equity in neovasc
    		                                                    
      redemption of series a preferred stock
    		                                                 0   
      borrowings under lines of credit
    		                                                 4,304,000   
      repayments under lines of credit
    		                                             -9,820,000 -10,798,000 -5,490,000  -4,916,000 -3,018,000 -2,827,000 
      cash and cash equivalents at beginning period
    		                                                    
      non-cash financing activities:
    		                                                    
      issuance of common stock to acquire farmadiet
    		                                                    
      (recovery of) benefit from bad debt
    		                                              60,000 -151,000     
      benefit from inventory reserves
    		                                              499,000 255,000     
      unrealized gain on investments, available for sale
    		                                                    
      contingent consideration
    		                                              965,000 1,144,000     
      borrowing under lines of credit
    		                                              11,216,000 10,337,000    3,027,000 
      proceeds from the exercise of stock options and warrants
    		                                              1,461,000 31,000 470,000 466,000 173,000 135,000 
      unrealized gain from warrants
    		                                               -1,117,000     
      cash flows from investing activities
    		                                                    
      write-off of acquired in-process research and development
    		                                                    
      foreign currency remeasurement
    		                                                    
      acquisition of rolapitant
    		                                                    
      maturities of marketable securities
    		                                                    
      issuance of series d preferred stock and warrants, including related parties
    		                                                    
      proceeds from bridge loan with related party
    		                                                    
      repayment of bridge loan with related party
    		                                                    
      net change in cash and cash equivalents
    		                                                    
      income from continuing operations
    		                                                    
      benefit from (recovery of) bad debt
    		                                                   28,000 
      changes in:
    		                                                    
      cash from operating activities from discontinuing operations
    		                                                    
      investment in neovasc
    		                                                    
      repayment of line of credit with related party
    		                                                    
      issuance of capital stock to acquire exakta-opko
    		                                                    
      equity-based compensation — employees and non-employees
    		                                                  1,744,000 1,754,000 
      benefit from (reversal of) inventory reserves
    		                                                  294,000 62,000 
      cash flows from investing activity
    		                                                    
      net cash from investing activity
    		                                                   -70,629,000 
      repayments of notes payable and capital lease obligations
    		                                                    
      impairment of goodwill
    		                                                    
      equity based compensation — employees and non-employees
    		                                                    
      foreign exchange
    		                                                    
      loss on disposal of assets
    		                                                    
      license of product for equity
    		                                                    
      issuance of common stock for cash to related party
    		                                                    
      insurance financing and borrowings on lines of credit
    		                                                    
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.